Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) released its earnings results on Tuesday. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.09, Morningstar.com reports.

Verona Pharma PLC American Depositary Share (NASDAQ VRNA) remained flat at $12.11 on Wednesday. The stock had a trading volume of 5,638 shares. The company’s market cap is $77.75 million. Verona Pharma PLC American Depositary Share has a one year low of $11.03 and a one year high of $50.88. The firm has a 50-day moving average of $14.17 and a 200-day moving average of $13.93.

A hedge fund recently bought a new stake in Verona Pharma PLC American Depositary Share stock. Vivo Capital LLC bought a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 704,225 shares of the company’s stock, valued at approximately $8,208,000. Verona Pharma PLC American Depositary Share comprises about 2.1% of Vivo Capital LLC’s portfolio, making the stock its 11th largest position. Vivo Capital LLC owned approximately 10.97% of Verona Pharma PLC American Depositary Share as of its most recent SEC filing. Institutional investors own 5.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Verona Pharma PLC American Depositary Share (VRNA) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/08/verona-pharma-plc-american-depositary-share-vrna-announces-earnings-results-misses-estimates-by-0-10-eps.html.

Several equities research analysts recently weighed in on VRNA shares. SunTrust Banks, Inc. started coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, May 22nd. They issued a “buy” rating and a $26.00 target price for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $26.00 target price on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, May 22nd. Stifel Nicolaus began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued a “buy” rating and a $22.00 price target for the company. Wedbush began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They issued an “outperform” rating and a $25.00 price target for the company. Finally, Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Tuesday, July 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.60.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.